Quick Answer
VitaNova Life Sciences Corp reported Total Revenue of $2.66 million for the year ending 2025.
- VitaNova Life Sciences Corp showed an increase of +366.5% in Total Revenue from 2024 to 2025.
- This data is from VitaNova Life Sciences Corp's annual report (Form 10-K), filed with the SEC on July 24, 2025.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $18.4 thousand | Q4 2017: $0.00 | Q1 2018: $0.00 | Q3 2018: $0.00 | Q4 2018: $0.00 | Q1 2019: $0.00 | Q3 2019: $0.00 | Q4 2019: $0.00 | Q1 2020: $0.00 | Q3 2020: $0.00 | Q4 2020: $0.00 | Q1 2021: $0.00 | Q3 2021: $0.00 | Q4 2021: $45.0 thousand | Q1 2022: $30.0 thousand | Q3 2022: $15.0 thousand | Q4 2022: $10.0 thousand | Q1 2023: $10.0 thousand | Q3 2023: $0.00 | Q3 2023: $0.00 | Q4 2023: $0.00 | Q4 2023: $0.00 | Q1 2024: $26.1 thousand | Q1 2024: $26.1 thousand | Q3 2024: $108.5 thousand | Q4 2024: $292.1 thousand | Q1 2025: $308.3 thousand | Q3 2025: $103.9 thousand | Q4 2025: $427.1 thousand | Q1 2026: $709.6 thousand.
- Historical annual values: Fiscal year 2025: $2.66 million | Fiscal year 2024: $570.7 thousand | Fiscal year 2023: $38.0 thousand | Fiscal year 2023: $38.0 thousand | Fiscal year 2022: $120.0 thousand | Fiscal year 2021: $0.00 | Fiscal year 2020: $0.00 | Fiscal year 2019: $0.00 | Fiscal year 2018: $0.00 | Fiscal year 2017: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: